Literature DB >> 21175445

(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.

Andrea L Gordon1, Olga V Lopatko, Andrew A Somogyi, David J R Foster, Jason M White.   

Abstract

AIMS: The aim of this study was to compare the transfer of buprenorphine and methadone between maternal and cord blood in women under chronic dosing conditions and to determine if differences exist in the transfer of the two methadone enantiomers.
METHODS: Maternal and cord blood samples were collected at delivery from women maintained on methadone (35, 25-140 mg day⁻¹) (median; range) or buprenorphine (6.00, 2-20 mg day⁻¹) during pregnancy. Plasma concentration ratios are presented as an indicator of foetal exposure relative to the mother.
RESULTS: Methadone was quantified in all samples, with cord : maternal plasma methadone concentration ratios (n= 15 mother-infant pairs) being significantly higher (P < 0.0001; mean difference (MD) 0.07; 95% confidence interval (CI) 0.048, 0.092) for the active (R)-methadone enantiomer (0.41; 0.19, 0.56) (median; range) compared with (S)-methadone (0.36; 0.15, 0.53). (R)- : (S)-methadone concentration ratios were also significantly higher (P < 0.0001; MD 0.24 95% CI 0.300, 0.180) for cord (1.40; 0.95, 1.67) compared with maternal plasma (1.16; 0.81, 1.38). Half the infant buprenorphine samples were below the assay lower limit of quantification (LLOQ) (0.125 ng ml⁻¹). The latter was four-fold lower than the LLOQ for methadone (0.50 ng ml⁻¹). The cord : maternal plasma buprenorphine concentration ratio (n= 9 mother-infant pairs) was 0.35; 0.14, 0.47 and for norbuprenorphine 0.49; 0.24, 0.91.
CONCLUSIONS: The transfer of the individual methadone enantiomers to the foetal circulation is stereoselective. Infants born to buprenorphine maintained women are not exposed to a greater proportion of the maternal dose compared with methadone and may be exposed to relatively less of the maternal dose compared with infants born to women maintained on methadone during pregnancy.
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175445      PMCID: PMC3014073          DOI: 10.1111/j.1365-2125.2010.03759.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  40 in total

1.  Transplacental transfer and metabolism of buprenorphine.

Authors:  Tatiana Nanovskaya; Sujal Deshmukh; Monica Brooks; Mahmoud S Ahmed
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

Authors:  Sarah D McAleer; Richard J Mills; Torsten Polack; Tanweer Hussain; Paul E Rolan; Alan D Gibbs; Frank G P Mullins; Ziad Hussein
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

4.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

5.  Methadone assays in pregnant women and progeny.

Authors:  G Blinick; C E Inturrisi; E Jerez; R C Wallach
Journal:  Am J Obstet Gynecol       Date:  1975-03-01       Impact factor: 8.661

6.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

7.  Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

Authors:  R E Johnson; H E Jones; D R Jasinski; D S Svikis; N A Haug; L M Jansson; W B Kissin; G Alpan; M E Lantz; E J Cone; D G Wilkins; A S Golden; G R Huggins; B M Lester
Journal:  Drug Alcohol Depend       Date:  2001-06-01       Impact factor: 4.492

8.  Buprenorphine and major metabolites in blood specimens collected for drug analysis in law enforcement purposes.

Authors:  Stephanie Oechsler; Gisela Skopp
Journal:  Forensic Sci Int       Date:  2009-12-16       Impact factor: 2.395

9.  Methadone metabolism by human placenta.

Authors:  Tatiana N Nanovskaya; Sujal V Deshmukh; Ilona A Nekhayeva; Olga L Zharikova; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biochem Pharmacol       Date:  2004-08-01       Impact factor: 5.858

10.  Aromatase is the major enzyme metabolizing buprenorphine in human placenta.

Authors:  Sujal V Deshmukh; Tatiana N Nanovskaya; Mahmoud S Ahmed
Journal:  J Pharmacol Exp Ther       Date:  2003-06-13       Impact factor: 4.030

View more
  5 in total

1.  The worldwide opioid epidemic: implications for treatment and research in pregnancy and the newborn.

Authors:  David Knoppert
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Buprenorphine, Norbuprenorphine, R-Methadone, and S-Methadone Upregulate BCRP/ABCG2 Expression by Activating Aryl Hydrocarbon Receptor in Human Placental Trophoblasts.

Authors:  Naveen K Neradugomma; Michael Z Liao; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2016-12-14       Impact factor: 4.436

3.  Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Authors:  Amber M Holbrook; Hendree E Jones; Sarah H Heil; Peter R Martin; Susan M Stine; Gabriele Fischer; Mara G Coyle; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

Review 4.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

5.  Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.

Authors:  Ingrid F Metzger; Anna E Thomas; Cindy A Evrard; David R Jones; Andrea R Masters; David M Haas; Laura S Haneline; Sara K Quinney
Journal:  Am J Perinatol       Date:  2020-02-12       Impact factor: 3.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.